Product Description
Acetylcholine Chloride is the chloride salt form of acetylcholine, a synthetic, quaternary amino alcohol with cholinergic properties. Acetylcholine chloride mimics the parasympathomimetic effect of the endogenous compound acetylcholine. Administered as an ophthalmic solution, this drug stimulates the cholinoceptors in the sphincter muscle of the iris, causing the pupil to constrict. (NCI05)
Mechanisms of Action: AChR Agonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Intramuscular, Transdermal, Oral, Topical, Intraocular, Intravenous
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | Canada | Chile | Colombia | Finland | France | Germany | Greece | Ireland | Italy | Japan | Jordan | Korea | Lebanon | Luxembourg | Malta | Mexico | Netherlands | New Zealand | Peru | Portugal | Singapore | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | United Kingdom | United States | Venezuela
Approved Indications: None
Company: Bristol-Myers Squibb
Company Location: Eastern America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Sweden
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Healthy Volunteers|Myasthenia Gravis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2024-515627-10-00 |
TLZ-C-001 | P2 |
Not yet recruiting |
Myasthenia Gravis |
2026-11-30 |
2025-05-02 |
Treatments |
|
2025-524564-38-00 |
CN0140003 | P1 |
Not yet recruiting |
Healthy Volunteers |
2026-12-23 |
|||
2018-004624-11 |
2018-004624-11 | P2 |
Active, not recruiting |
Healthy Volunteers |
2021-03-13 |
2022-03-13 |
Treatments |
